Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Plainer, S; Wenzl, E; Saalabian, AA; Wohlfart, C; Vidic, B; El-Shabrawi, Y; Ardjomand, N.
Long-term follow-up with I-care phakic IOLs.
Br J Ophthalmol. 2011; 95(5): 710-714.
Doi: 10.1136/bjo.2009.172650
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Ardjomand Navid
- Co-Autor*innen der Med Uni Graz
- El-Shabrawi Yosuf
- Vidic Bertram
- Wissiak Elfriede
- Wohlfart Christina
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Aim To evaluate visual quality and postoperative results as well adverse events in myopic patients undergoing I-CARE anterior-chamber angle-supported phakic intraocular lens (IOL) implantation. Design A retrospective, non-randomised, case series. Participants Data on 29 eyes (16 patients) receiving I-CARE phakic IOL for high myopia (-11.66+/-3.3) were analysed. Methods The IOLs were implanted between 2003 and 2006 at the Department of Ophthalmology, Medical University, Graz, Austria. The mean follow-up was 51.7+/-16 months (17-78 months). Main outcome measures The authors measured uncorrected visual acuity (UCVA) and best-corrected visual acuity (BCVA); patients underwent slit-lamp examination, corneal topography, Scheimpflug imaging and measurement of endothelial cells (EC). Results The mean UCVA and BCSVA were 0.63 and 0.94 decimal after 1 year. Endothelial cell loss was the most serious adverse event observed. The mean EC loss was 2%, 9%, 17%, 21%, 33% and 47% after 1 year (n=17), 2 years (n=20), 3 years (n=17), 4 years (n=17), 5 years (n=12) and 6 years (n=3), respectively. Eight IOL explantations were made due to severe EC loss 3-6 years after implantation. Other serious complications included one patient with Urrets-Zavalia Syndrome (one eye). Conclusion Implantation of the I-CARE phakic-IOL is not a safe method for the correction of high myopia due to serious endothelial cell loss that might occur in a high number of patients. Patients with these IOLs should be followed up at least every 6 months, and the IOL should be explanted, once the EC count drops to less than 2000 cells/mm(2).
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Adult -
- Endothelium, Corneal - physiopathology
- Female -
- Follow-Up Studies -
- Humans -
- Lens Implantation, Intraocular - methods
- Male -
- Middle Aged -
- Myopia - physiopathology
- Retrospective Studies -
- Treatment Outcome -
- Visual Acuity - physiology